outbreak
sever
acut
respiratori
syndrom
coronaviru
infect
caus
coronaviru
diseas
report
china
sinc
decemb
patient
develop
acut
respiratori
distress
syndrom
fatal
ratio
specif
treatment
report
herein
examin
effect
favipiravir
fpv
versu
lopinavir
lpv
ritonavir
rtv
treatment
patient
laboratoryconfirm
receiv
oral
fpv
day
mg
twice
daili
day
mg
twice
daili
plu
interferon
ifn
aerosol
inhal
million
u
twice
daili
includ
fpv
arm
studi
wherea
patient
treat
lpvrtv
day
mg
twice
daili
plu
ifna
aerosol
inhal
million
u
twice
daili
includ
control
arm
chang
chest
comput
tomographi
ct
viral
clearanc
drug
safeti
compar
two
group
patient
enrol
fpv
arm
patient
control
arm
baselin
characterist
compar
two
arm
shorter
viral
clearanc
time
found
fpv
arm
versu
control
arm
median
interquartil
rang
iqr
versu
p
fpv
arm
also
show
signific
improv
chest
imag
compar
control
arm
improv
rate
versu
p
adjust
potenti
confound
fpv
arm
also
show
significantli
higher
improv
rate
chest
imag
multivari
cox
regress
show
fpv
independ
associ
faster
viral
clearanc
addit
fewer
advers
reaction
found
fpv
arm
control
arm
openlabel
nonrandom
control
studi
fpv
show
significantli
better
treatment
effect
term
diseas
progress
viral
clearanc
causal
result
import
inform
establish
standard
treatment
guidelin
combat
infect
recent
outbreak
coronaviru
diseas
caus
novel
coronaviru
design
sever
acut
respiratori
syndrom
coronaviru
start
wuhan
china
end
clinic
characterist
includ
respiratori
symptom
fever
cough
dyspnea
pneumonia
februari
least
case
death
identifi
across
china
countri
particular
case
identifi
south
korea
japan
respect
outbreak
alreadi
caus
global
alarm
januari
world
health
organ
reveal
genom
sequenc
ident
sarscov
similar
sever
bat
coronavirus
seventh
report
humaninfect
member
famili
coronavirida
also
includ
sarscov
middl
east
respiratori
syndrom
mer
cov
identifi
caus
agent
clinic
epidemiolog
featur
patient
demonstr
infect
lead
intens
care
unit
icu
admiss
high
mortal
peopl
viru
china
becom
sever
ill
mortal
rate
howev
specif
treatment
new
viru
therefor
urgent
necessari
identifi
effect
antivir
agent
combat
diseas
explor
clinic
effect
antivir
drug
one
effici
approach
discov
effect
drug
test
whether
exist
antivir
drug
effect
treat
relat
viral
infect
sever
drug
ribavirin
interferon
ifn
favipiravir
fpv
lopinavir
lpv
ritonavir
rtv
use
patient
sar
mer
although
efficaci
drug
remain
controversi
recent
demonstr
prodrug
fpv
half
maxim
effect
concentr
ec
halfmaxim
cytotox
concentr
cc
select
index
si
effect
inhibit
infect
vero
cell
furthermor
report
show
fpv
effect
protect
mice
ebola
viru
challeng
although
ec
valu
vero
cell
high
therefor
clinic
studi
urgent
need
evalu
efficaci
safeti
antivir
nucleosid
treatment
studi
perform
comprehens
evalu
clinic
efficaci
treatment
patient
third
peopl
hospit
shenzhen
aim
compar
clinic
effect
fpv
lpvrtv
patient
find
help
provid
guidanc
clinic
treatment
infect
specif
epidem
situat
chose
conduct
openlabel
nonrandom
control
studi
isol
ward
nation
clinic
research
center
infecti
diseas
third
peopl
hospit
shenzhen
shenzhen
china
januari
februari
laboratoryconfirm
patient
consecut
screen
elig
patient
includ
fpv
arm
studi
patient
initi
treat
antivir
therapi
lpvrtv
januari
januari
screen
elig
patient
includ
control
arm
studi
studi
conduct
accord
guidelin
declar
helsinki
principl
good
clinic
practic
approv
ethic
committe
third
peopl
hospit
shenzhen
written
inform
consent
obtain
patient
studi
report
accord
consolid
standard
report
trial
guidelin
regist
chines
clinic
trial
registri
id
patient
admit
fpv
control
arm
studi
assess
elig
criteria
inclus
criteria
includ
age
year
old
respiratori
blood
sampl
test
posit
novel
coronaviru
durat
diseas
onset
enrol
less
will
take
contracept
studi
within
treatment
difficulti
swallow
pill
exclus
criteria
includ
follow
sever
clinic
condit
meet
one
follow
criteria
rest
respiratori
rate
greater
per
minut
oxygen
satur
oxygen
index
oi
mmhg
mmhg
pa
respiratori
failur
shock
andor
combin
failur
organ
requir
icu
monitor
treatment
chronic
liver
kidney
diseas
reach
end
stage
previou
histori
allerg
reaction
fpv
lpvrtv
pregnant
lactat
women
women
childbear
age
posit
pregnanc
test
breastfeed
miscarriag
within
week
deliveri
particip
anoth
clinic
trial
treatment
current
past
fpv
haizheng
pharmaceut
co
mg
per
tablet
given
oral
dose
mg
twice
daili
day
mg
twice
daili
day
lpvrtv
abbvi
inc
mg
per
tablet
given
oral
dose
lpv
mgrtv
mg
twice
daili
fpv
lpvrtv
continu
viral
clearanc
confirm
pass
addit
particip
receiv
mg
beij
triprim
gene
pharmaceut
co
lg
per
ampul
twice
daili
aerosol
inhal
standard
care
includ
oxygen
inhal
oral
intraven
rehydr
electrolyt
correct
antipyret
analges
antiemet
drug
efficaci
treatment
assess
time
viral
clearanc
improv
rate
chest
comput
tomographi
ct
scan
day
treatment
chest
ct
scan
conduct
day
treatment
fluctuat
ct
find
grade
score
use
method
describ
previous
two
medic
diagnost
radiograph
blind
group
ct
find
grade
threepoint
scale
normal
attenu
groundglass
attenu
consolid
lung
zonewith
total
six
lung
zone
patientwa
assign
score
follow
scale
accord
distribut
affect
lung
parenchyma
use
method
modifi
previous
describ
protocol
normal
abnorm
abnorm
abnorm
abnorm
fourpoint
scale
lung
parenchyma
distribut
multipli
radiolog
scale
describ
point
zone
ad
final
total
cumul
score
valu
rang
fig
chang
improv
chest
ct
defin
total
cumul
score
lower
medic
chang
wors
defin
total
cumul
score
higher
medic
chang
constant
defin
total
cumul
score
treatment
fig
presenc
detect
realtim
quantit
polymeras
chain
reaction
qpcr
method
previous
report
viral
ribonucl
acid
rna
extract
sampl
use
qiaamp
rna
viral
kit
qiagen
hilden
germani
quantit
revers
transcript
polymeras
chain
reaction
qrtpcr
perform
use
commerci
kit
specif
detect
geneodx
co
ltd
shanghai
china
approv
china
food
drug
administr
cfda
rebrand
restructur
nation
medic
product
administr
state
administr
market
regul
prc
sinc
viral
clearanc
defin
presenc
two
consecut
neg
result
qpcr
detect
interv
h
safeti
assess
standard
questionnair
advers
event
laboratori
test
quantit
data
describ
mean
standard
deviat
median
minmax
qualit
data
describ
number
case
proport
patient
characterist
compar
use
v
test
fisher
exact
test
categor
data
wilcoxon
ranksum
test
student
test
continu
data
factor
affect
chang
chest
ct
analyz
use
binari
logist
regress
analysi
viral
clearanc
time
calcul
use
kaplanmei
method
differ
analysi
viral
clearanc
time
differ
treatment
calcul
use
logrank
test
potenti
influenc
factor
viral
clearanc
analyz
univari
multivari
cox
regress
model
p
valu
lower
requir
statist
signific
analysi
perform
use
spss
version
graphpad
prism
januari
patient
laboratoryconfirm
screen
elig
fpv
arm
studi
total
laboratoryconfirm
patient
start
treatment
lpvrtv
januari
januari
screen
elig
control
arm
studi
enrol
patient
finish
therapi
follow
treatment
began
fig
baselin
characterist
compar
fpv
arm
control
shown
tabl
signific
differ
baselin
characterist
two
arm
kaplanmei
surviv
curv
length
time
viral
clearanc
kind
antivir
therapi
present
fig
median
time
viral
clearanc
patient
treat
fpv
design
group
estim
iqr
significantli
shorter
time
patient
control
group
design
group
b
iqr
p
nonparametr
mannwhitney
u
test
use
determin
signific
differ
chest
ct
chang
respons
two
differ
treatment
tabl
meanwhil
improv
rate
chest
ct
chang
two
arm
studi
compar
day
treatment
signific
differ
improv
rate
found
two
arm
day
p
howev
day
treatment
improv
rate
chest
ct
chang
fpv
arm
significantli
higher
control
arm
versu
versu
p
furthermor
patient
divid
two
group
base
time
viral
shed
day
treatment
improv
rate
chest
ct
chang
group
viral
clearanc
within
treatment
significantli
higher
patient
viral
clearanc
treatment
fig
univari
analysi
use
v
test
test
wilcoxon
ranksum
test
conduct
multivari
analysi
signific
variabl
p
univari
analysi
follow
antivir
therapi
whether
fever
present
multivari
logist
regress
analysi
conduct
identifi
independ
factor
affect
chang
chest
ct
chose
chang
chest
ct
chang
wors
improv
depend
variabl
variabl
signific
univari
analysi
profession
signific
includ
age
underli
diseas
sever
diseas
baselin
independ
variabl
result
show
two
statist
signific
factor
model
antivir
therapi
odd
ratio
confid
interv
ci
fever
ci
mean
antivir
therapi
fever
independ
factor
affect
chest
ct
control
confound
factor
patient
treat
fpv
greater
improv
chest
ct
tabl
univari
analysi
use
logrank
test
univari
cox
regress
conduct
multivari
analysi
signific
variabl
p
univari
analysi
follow
antivir
therapi
white
blood
cell
wbc
hemoglobin
hb
platelet
plt
neutrophil
lymphocyt
count
ill
treatment
time
multivari
cox
regress
model
use
explor
independ
factor
affect
viral
clearanc
time
viral
clearanc
set
time
variabl
viral
clearanc
ye
set
statu
variabl
signific
p
univari
cox
analysi
profession
signific
includ
age
whether
underli
diseas
present
set
independ
variabl
result
show
model
signific
p
signific
factor
follow
lymphocyt
count
hazard
ratio
hr
ci
antivir
therapi
hr
ci
mean
treatment
lymphocyt
count
independ
factor
affect
viral
clearanc
control
confound
factor
result
show
compar
lpvrtv
fpv
greater
effect
viral
clearanc
tabl
total
number
advers
reaction
fpv
arm
studi
four
significantli
fewer
advers
reaction
control
arm
p
two
patient
diarrhea
one
liver
injuri
one
poor
diet
fpv
arm
meanwhil
five
patient
diarrhea
five
vomit
six
nausea
four
rash
three
liver
injuri
two
chest
tight
palpit
control
arm
tabl
studi
investig
effect
fpv
versu
lpvrtv
treatment
found
fpv
independ
associ
faster
viral
clearanc
higher
improv
rate
chest
imag
find
suggest
fpv
significantli
better
treatment
effect
term
diseas
progress
viral
clearanc
compar
lpvrtv
fpv
known
prodrug
novel
rnadepend
rna
polymeras
rdrp
inhibitor
shown
effect
treatment
influenza
ebola
viru
recent
report
wang
et
al
show
fpv
remdesivir
effect
reduc
infect
vitro
ec
cc
si
find
preset
studi
confirm
hypothes
conceiv
laboratori
find
fpv
effect
treatment
limit
present
studi
random
doubleblind
placebocontrol
clinic
trial
led
inevit
select
bia
patient
recruit
howev
given
high
number
patient
present
simultan
high
infect
diseas
ethic
unaccept
alloc
patient
receiv
differ
experiment
drug
use
random
process
imposs
patient
understand
furthermor
context
rumor
distrust
hospit
isol
use
random
design
outset
might
led
even
patient
refus
isol
therefor
chose
conduct
nonrandom
trial
patient
consecut
admit
hospit
two
separ
period
includ
two
group
respect
importantli
baselin
characterist
two
group
compar
effect
fpv
remain
signific
adjust
potenti
confound
current
studi
also
found
earli
viral
clearanc
contribut
improv
chest
imag
day
find
suggest
improv
diseas
may
depend
inhibit
fpv
control
diseas
progress
inhibit
recent
pathogenesi
well
clarifi
sinc
infect
thought
selflimit
character
system
inflamm
reaction
symptomat
support
treatment
mainli
recommend
nation
health
commiss
prc
descript
similar
merscov
nonspecif
therapeut
intervent
often
introduc
prevent
sever
mor
biditi
mortal
antivir
would
contribut
control
diseas
controversi
although
mani
regist
clinic
trial
focus
antivir
drug
time
durat
treatment
studi
endpoint
unifi
current
studi
time
viral
clearanc
introduc
primari
endpoint
evalu
antivir
effect
fpv
success
identifi
prioriti
fpv
relationship
time
viral
clearanc
improv
ct
imag
indic
viral
clearanc
ideal
surrog
clinic
endpoint
limit
present
studi
relationship
viral
titer
clinic
prognosi
well
clarifi
futur
research
could
pay
attent
point
advers
event
observ
control
arm
experiment
arm
similar
advers
event
observ
studi
aid
treat
lpvrtv
worth
mention
treatment
durat
fpv
present
studi
twice
long
use
treatment
influenza
howev
advers
event
experiment
arm
rare
toler
none
patient
need
discontinu
fpv
treatment
result
seem
suggest
treatment
durat
fpv
prolong
necessari
infect
spread
quickli
world
present
effect
treatment
demonstr
task
hand
run
welldesign
trial
identifi
effect
treatment
base
high
level
evid
howev
begin
studi
certain
condit
allow
random
patient
receiv
either
standard
care
experiment
drug
pilot
studi
nonrandom
control
trial
found
fpv
show
significantli
better
treatment
effect
term
diseas
progress
viral
clearanc
causal
result
import
inform
establish
standard
treatment
guidelin
combat
infect
furthermor
introduc
time
viral
clearanc
primari
endpoint
experiment
antivir
treatment
demonstr
surrog
clinic
endpoint
help
design
research
lei
liu
yingxia
liu
qingxian
cai
minghui
yang
jun
chen
contribut
studi
design
qingxian
cai
minghui
yang
dan
shu
junxia
xia
xuejiao
liao
dongj
liu
yuanbo
gu
qiue
cai
xiaoh
li
jiay
liu
lin
g
peng
deliang
huang
jing
zhang
contribut
collect
clinic
data
qingxian
cai
minghui
yang
shurong
zhang
fuxiang
wang
li
chen
shuyan
chen
zhaoqin
wang
zheng
zhang
contribut
data
analysi
qingxian
cai
minghui
yang
jun
chen
yang
yang
chenguang
shen
ruiyuan
cao
wu
zhong
contribut
manuscript
prepar
author
read
approv
manuscript
